BioCentury | Mar 28, 2021
Finance

Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO

...Technology and Quality Officer Heow Tan, who held the same position at Pharmacyclics.Pharmacyclics developed Imbruvica ibrutinib...
BioCentury | Mar 13, 2021
Product Development

Why Loxo is leaning on internal discovery as Lilly’s R&D unit

...inhibitors on the market such as Imbruvica ibrutinib...
...will test the covalent inhibitor head-to-head against Imbruvica.Without...
BioCentury | Jan 26, 2021
Regulation

Jan. 25 Quick Takes: Comirnaty approved in Australia, authorized in Hong Kong; plus Albireo, Iterum and AZ

...non-inferior progression-free survival in adults with previously treated, high-risk chronic lymphocytic leukemia compared to Imbruvica ibrutinib...
...A4250) Sulopenem etzadroxil-probenecid (PF-03709270) Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) Imbruvica (Brand), PCI-32765 (Compound #), ibrutinib (Generic), Imbruvica...
BioCentury | Dec 15, 2020
Deals

ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

...LOTIS 3 study evaluating Lonca with Ibrance ibrutinib...
BioCentury | Dec 7, 2020
Product Development

Loxo to take on Imbruvica after reversible Btk inhibitor shines at ASH

...inhibitor Imbruvica ibrutinib, but it also raises the question of how it stacks up to Imbruvica...
...a Phase III study against Imbruvica in treatment-naïve CLL/SLL scheduled to begin later in the year.Imbruvica...
...tyrosine kinaseRET – Ret proto-oncogene Lauren Martz LY3527727 (LOXO-305, REDX08608, rxc005) Imbruvica (Brand), PCI-32765 (Compound #), ibrutinib (Generic), Imbruvica...
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...NYSE:ABBV) for documents regarding pricing strategies for autoimmune drug Humira adalimumab and cancer therapy Imbruvica ibrutinib...
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

...the Btk inhibitor to compete with Imbruvica ibrutinib...
...lymphoma (SLL) and mantle cell lymphoma (MCL). Imbruvica...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...program off the ground. Sales from AbbVie’s two marketed cancer drugs, Venclexta venetoclax and Imbruvica ibrutinib...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...royalty transactions since 1996, including deals for 45 marketed therapies. Among them are blockbusters Imbruvica ibrutinib...
BioCentury | Apr 27, 2020
Finance

ADC renews IPO bid as first regulatory filing looms

...targets CD19. In a separate Phase I/II trial evaluating loncastuximab tesirine plus Btk inhibitor Imbruvica ibrutinib...
Items per page:
1 - 10 of 384